The group's principal activity is to develop advanced needle-free drug delivery systems for the treatment of lung and systemic diseases. The group's hand-held aerx platform is being designed for reproducible delivery of pharmaceutical drugs and biotech compounds via pulmonary delivery or through the lung. The pen-sized needle-free subcutaneous intraject system is designed to deliver drugs to the subcutaneous region of the skin where it can gain access to the bloodstream. Aerx and intraject systems perform equivalent to injection will be alternative to injection-based drug delivery. During the year 2003, the group acquired selected assets of weston medical.
